Skip to main content

June 10: VDP Formulary, CAD, MCO Search Realignment Now Active

Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

3. Duplicative Therapy

There are no FDA indications for duplicate therapy with multiple combination drug products (e.g. ledipasvir/ sofosbuvir (Harvoni) with glecaprevir/ pibrentasvir (Mavyret))2,4-8,10.

Ribavirin combination therapy is indicated in patients with more advanced liver disease and HCV genotypes that are found to be more resistant (e.g. genotype 3)1,2,4,6-8,11.

For recommended combination therapies see Duration of Therapy tables above (Tables 1-3).